2. Search Result
Search Result
Results for "

dual functional

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Screening Libraries

2

Biochemical Assay Reagents

1

Click Chemistry

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-135140
    Methyltetrazine-amine

    		Biochemical Assay Reagents Others
    Methyltetrazine-amine, a tetrazine compound, is used for the site-specific dual functionalization of the resulting bioconjugates .
    Methyltetrazine-amine
  • HY-135140A
    Methyltetrazine-amine hydrochloride

    		Biochemical Assay Reagents Others
    Methyltetrazine-Amine hydrochloride is a tetrazine compound. Methyltetrazine-Amine hydrochloride can be used for the site-specific dual functionalization of the resulting bioconjugates. Methyltetrazine-Amine hydrochloride can be added during protein precipitation in experiments using trans-cyclooctene .
    Methyltetrazine-amine hydrochloride
  • HY-D0976
    NF279

    		P2X Receptor HIV Infection
    NF279 is a potent selective and reversible P2X1 receptor antagonist, with an IC50 of 19 nM. NF279 displays good selectivity over P2X2, P2X3 (IC50=1.62 μM), P2X4 (IC50>300 μM). NF279 is a dual HIV-1 coreceptor inhibitor that interferes with the functional engagement of CCR5 and CXCR4 by Env .
    NF279
  • HY-122462
    Ladirubicin

    PNU-159548

    		 DNA/RNA Synthesis Cancer
    Ladirubicin (PNU-159548) is a derivative of Daunorubicin (HY-13062A). Ladirubicin exhibits DNA intercalation and DNA alkylating properties, inhibits DNA replication and transcription, causes DNA damage, and thereby exhibits antitumor efficacy. Ladirubicin exhibits the potential to penetrate the blood-brain barrier (BBB) for its high lipophilicity. Ladirubicin exhibits toxicity through suppression of bone marrow activity .
    Ladirubicin
  • HY-120785A
    SR1555 hydrochloride

    		ROR Inflammation/Immunology
    SR1555 hydrochloride is the hydrochloride salt form of SR1555 (HY-120785). SR1555 hydrochloride is an inverse agonist for retinoic acid receptor-related orphan nuclear receptor γ (RORγ) with an IC50 of 1 μM. SR1555 hydrochloride inhibits the development and function of pro-inflammatory TH17 cell, increases the frequency of anti-inflammatory T regulatory (Treg) cells. SR1555 hydrochloride can be used for research about autoimmune diseases .
    SR1555 hydrochloride
  • HY-W127819
    Phenyleneethylenetriamine pentaacetic acid

    		Biochemical Assay Reagents Others
    Phenyleneethylenetriamine Pentaacetic Acid is a precursor of a dual functional chelating agent .
    Phenyleneethylenetriamine pentaacetic acid
  • HY-175607
    AChE/nAChR-IN-1

    		Cholinesterase (ChE) nAChR Infection Neurological Disease
    AChE/nAChR-IN-1 (Compound 1a) is dual-functional inhibitor of AChE and nAChR. AChE/nAChR-IN-1 has potent toxicity and larvicidal effectiveness against Culex pipiens larvae with a LC50 of 4 ng/mL. AChE/nAChR-IN-1 can be used as larvicides for mosquito-borne diseases research .
    AChE/nAChR-IN-1
  • HY-175197
    MP1202

    		Opioid Receptor Arrestin Neurological Disease
    MP1202 is a dual-functional agonist of MOR and KOR with EC50s of 0.32 and 0.13  μM for mMOR-1 and mKOR-1, respectively. MP1202 has functional selectivity with reduction of β-arrestin1/2 recruitment but significant activation of G-protein and Gα-subtype at hMOR and hKOR. MP1202 has potent antinociceptive effects without typical opioid side effects, but it shows conditioned place preference and aversion behaviors in subtype-selective opioid KO mice model, promising for analgesia research .
    MP1202
  • HY-175219
    CA-II/Dkk1-IN-1

    		Carbonic Anhydrase Cancer
    CA-II/Dkk1-IN-1 (Compound 5d) is a dual-functional inhibitor of CA-II and Dkk1 with a IC50 of 6.90  nM for CA-II. CA-II/Dkk1-IN-1 has significantly antioxidant activity and superior DNA binding capacity. CA-II/Dkk1-IN-1 can be used for cancers research, such as esophageal, renal, and lung cancer .
    CA-II/Dkk1-IN-1
  • HY-175605
    α-Amylase/α-Glucosidase-IN-21

    		Glycosidase Amylases Metabolic Disease
    α-Amylase/α-Glucosidase-IN-21 (Compound 4) is a dual-functional inhibitor of α-Glucosidase and α-Amylase with IC50s of 0.27 and  0.19 µg/mL for α-Glucosidase and α-Amylase, respectively. α-Amylase/α-Glucosidase-IN-21 has an antidiabetic activity.α-Amylase/α-Glucosidase-IN-21 can be used for diabetes mellitus research .
    α-Amylase/α-Glucosidase-IN-21
  • HY-175635
    EGFR/VEGFR2-IN-6

    		EGFR VEGFR Cancer
    EGFR/VEGFR2-IN-6 (Compound 3k) is a dual-functional inhibitor of EGFR and VEGFR2 with IC50s of 10.53 and 3.37 μM for EGFR and VEGFR2, respectively. EGFR/VEGFR2-IN-6 has significant anti-proliferation activity against breast cancer cells, and induces G0/G1 cell cycle arrest and cell apoptosis, especially early apoptosis. EGFR/VEGFR2-IN-6 can be used for cancers research .
    EGFR/VEGFR2-IN-6
  • HY-175805
    EGFR/HDAC-IN-2

    		EGFR HDAC Apoptosis Cancer
    EGFR/HDAC-IN-2 (Compound 38) is dual-functional inhibitor of EGFR and HDAC3 with IC50s of 20.34 and 1.09 nM for CDK9 and HDAC3, respectively. EGFR/HDAC-IN-2 has superior anti-proliferative activity against cancer cells, inhibits cell migration and induces late-stage cell apoptosis. EGFR/HDAC-IN-2 significantly inhibits triple-negative breast cancer (TNBC) tumor growth in xenograft mouse models. EGFR/HDAC-IN-2 can be used for cancers like TNBC research .
    EGFR/HDAC-IN-2
  • HY-153229
    Firefly luciferase mRNA-LNP
    1 Publications Verification

    		 mRNA Biochemical Assay Reagents Others
    Firefly luciferase mRNA-LNP is a lipid nanoparticle (LNP) containing firefly luciferase mRNA. Firefly luciferase mRNA-LNP exhibits a stable nanostructure, in which LNP plays a key role in effectively protecting and transporting mRNA to cells. Luciferase is a bioluminescent reporter gene for gene regulation and functional studies. Firefly Luciferase mRNA-LNP expresses firefly luciferase protein after entering the cells, which is often used for promoter activity detection or dual fluorescent molecular complementation experiments. Firefly luciferase mRNA-LNP is studied in research for RNA delivery, cell viability, and translation efficiency .
    Firefly luciferase mRNA-LNP
  • HY-172891
    CDK9/HDAC1/HDAC3-IN-1

    		CDK HDAC Apoptosis Cancer
    CDK9/HDAC1/HDAC3-IN-1 is dual-functional inhibitor of CDK9 and HDAC. CDK9/HDAC1/HDAC3-IN-1 inhibits the protein activity of CDK9/HDAC/HDAC3 with IC50 s of 0.17  μM, 1.73  μM and 1.11 μM for CDK9, HDAC1, and HDAC3, respectively. CDK9/HDAC1/HDAC3-IN-1 inhibits cancer cells by inducing cell apoptosis and cell cycle arrest in the G2/M phase, as well as tumor growth in a murine TNBC MDA-MB-231 xenograft model. CDK9/HDAC1/HDAC3-IN-1 has a broad-spectrum anti-cancer activity, such as breast cancer, cervical cancer, and liver cancer .
    CDK9/HDAC1/HDAC3-IN-1
  • HY-117947
    (R)-OR-S1

    		Histone Methyltransferase Cancer
    (R)-OR-S1 is an isomer of OR-S1. The dual ZH1/2 inhibitors OR-S1 and OR-S2 exhibit strong inhibitory activity against both EZH1 and EZH2. OR-S1 and OR-S2 are highly selective methyltransferase inhibitors against EZH1 and EZH2, and they have very similar molecular features. Therefore, we investigated the effect of OR-S1 on acute myeloid leukemia (AML). We found that OR-S1 was able to induce cell differentiation and apoptosis in AML cells. These findings encouraged us to investigate whether functional LT-HSCs could survive PRC2-targeted therapy with OR-S1 or OR-S1 combined with cytarabine. The results showed that OR-S1 did not cause significant myelosuppression, and BM cells treated with the combination therapy were able to undergo normal hematopoiesis even 4 months after treatment. Therefore, temporary inhibition of EZH1 and EZH2 is clinically tolerable, making this combination therapy suitable for AML patients. AML is generally believed to originate from myeloid progenitor cells that inherit a large number of biological properties.
    (R)-OR-S1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: